**FOI Ref: 6038**

**Category(ies): Clinical - Drugs**

**Subject: The usage of anti-VEGF treatments for eye conditions**

**Date Received: 28/09/21**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatements:   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Fluocinolone acetonide * Ranibizumab | 314  0  47  13  27  483 |
| 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Fluocinolone acetonide * Ranibizumab | 7  0  3  0  0  15 |
| 3. Within your trust, how many intra-vitreal injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Ranibizumab | 705  0  91  13  1054 |
| 4. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Ranibizumab | 368  0  91  0  571 |